Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
The data suggest that host genetics may be useful for the prediction of drug response, and they also support the investigation of the role of IL28B in the treatment of HCV and in other diseases treated with IFN-α.
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
The association of the IL28B locus with natural and treatment-associated control of HCV indicates the importance of innate immunity and interferon lambda in the pathogenesis ofHCV infection.
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
In patients with H beAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression, and HBsAg serconversion.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in patients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of sustained virology response.
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Extended treatment duration generally is not recommended in HCV type 1 infection and should be reserved only for patients with slow virologic response defined as HCV-RNA positive at week 12 but negative at week 24, which is seen in patients with low-level viremia at weeks 12.
A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis
A genome-wide association study for alcohol-related cirrhosis in individuals of European descent with subsequent validation in two independent European cohorts is performed, suggesting that lipid turnover is important in the pathogenesis of alcohol- related Cirrhosis.
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.